These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 30153192)
41. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Malloy MJ; Kane JP Adv Intern Med; 2001; 47():111-36. PubMed ID: 11795072 [TBL] [Abstract][Full Text] [Related]
42. Fibrates and niacin: is there a place for them in clinical practice? Wierzbicki AS; Viljoen A Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657 [TBL] [Abstract][Full Text] [Related]
43. [Hypertricglyceridemia: prognostic impact and treatment options]. Custodis F; Laufs U Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752 [TBL] [Abstract][Full Text] [Related]
44. Bloodletting to Treat Severe Hypertriglyceridemia. Koehler P; Bröckelmann PJ; Md MH; Kochanek M Ann Intern Med; 2019 Jul; 171(2):142-143. PubMed ID: 30802899 [No Abstract] [Full Text] [Related]
45. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. Rabar S; Harker M; O'Flynn N; Wierzbicki AS; BMJ; 2014 Jul; 349():g4356. PubMed ID: 25035388 [No Abstract] [Full Text] [Related]
46. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Chait A; Eckel RH Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285 [TBL] [Abstract][Full Text] [Related]
47. Hypertriglyceridemia-why, when and how should it be treated? Gouni-Berthold I; Krone W Z Kardiol; 2005 Nov; 94(11):731-9. PubMed ID: 16258774 [TBL] [Abstract][Full Text] [Related]
56. Dyslipidemia in the elderly: should it be treated? Shanmugasundaram M; Rough SJ; Alpert JS Clin Cardiol; 2010 Jan; 33(1):4-9. PubMed ID: 20063295 [TBL] [Abstract][Full Text] [Related]
57. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
58. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. Talasaz AH; Sadeghipour P; Aghakouchakzadeh M; Dreyfus I; Kakavand H; Ariannejad H; Gupta A; Madhavan MV; Van Tassell BW; Jimenez D; Monreal M; Vaduganathan M; Fanikos J; Dixon DL; Piazza G; Parikh SA; Bhatt DL; Lip GYH; Stone GW; Krumholz HM; Libby P; Goldhaber SZ; Bikdeli B J Am Coll Cardiol; 2021 Oct; 78(16):1635-1654. PubMed ID: 34649702 [TBL] [Abstract][Full Text] [Related]
59. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. Brinton EA Cardiol Clin; 2015 May; 33(2):309-23. PubMed ID: 25939302 [TBL] [Abstract][Full Text] [Related]
60. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]